Interleukin-17 and type 17 helper T cells.

By P. Miossec, T. Korn, V. Kuchroo. New England Journal of Medicine, 2009

1,462 citations recorded by the source corpus.

Subfields: Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/7eba1300b3b7cac80e2c4ba2d3e5ad0bed23d773

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Pathology and Forensic Medicine

R. Flavell

Citations in the corpus

Th17 cells express interleukin-10 receptor and are controlled by Foxp3− and Foxp3+ regulatory CD4+ T cells in an interleukin-10 dependent manner (2011, background): “Th17 cells express the transcription factor RORgt, which induces transcription of the Il17A gene (Annunziato et al., 2009; Miossec et al., 2009).”
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis (2009, positive): “These cells have been identified within the pool of circulating CD4þCD45ROþ (memory) T cells (Miossec et al., 2009).”
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis (2010, background): “E-mail: office.patel@novartis.com †The investigators in the Psoriasis Study Group, the Rheumatoid Arthritis Study Group, and the Uveitis Study Group are listed in the Supplementary Material. www.Sci by TH17 cells, which derive from naïve CD4 + T cells after stimulation by transforming growth factor–”
MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis (2009, background): “, and regulators of T H -17 differentiation are considered to have valuable potential for clinical applications in the diagnosis or treatment of this category of complicated immune disorder”
Melatonin: Buffering the Immune System (2013, background): “Th17 cells, a novel subset of CD4+ T cells, have mainly been identified on the basis of RORγt transcription factor expression and the production of IL-17 [15].”
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. (2012, neutral): “Injection-site erythema 1 (3) 1 (3) 1 (3) 3 (8) 4 (10) 9 (6)”